Skip to main content
IMNN
NASDAQ Life Sciences

Imunon Appoints Former CFO Jeffrey Church as Interim CFO Following Kimberly Graper's Resignation

Analysis by Wiseek.aiReviewed by Editorial Team
Sentiment info
Neutral
Importance info
7
Price
$3.88
Mkt Cap
$13.329M
52W Low
$2.99
52W High
$41.217
Market data snapshot near publication time

summarizeSummary

Imunon, Inc. announced the resignation of its interim Chief Financial Officer, Kimberly Graper, and the immediate appointment of former CFO Jeffrey Church to the interim role, ensuring continuity in financial leadership.


check_boxKey Events

  • Interim CFO Resignation

    Kimberly Graper resigned from her role as interim Chief Financial Officer, effective January 14, 2026, to pursue another career opportunity. The company stated her departure was without any disagreements with management.

  • Interim CFO Appointment

    Jeffrey Church, the company's former Executive Vice President, Chief Financial Officer, and Corporate Secretary, was appointed as interim Chief Financial Officer, effective January 14, 2026. Mr. Church had been in a consulting role since his retirement in May 2024.

  • Consulting Agreement Amended

    Mr. Church's consulting agreement was amended to provide a monthly retainer of $30,000, plus an additional $250 for each hour of services performed in excess of 40 hours per month during an extended consulting period.


auto_awesomeAnalysis

Imunon, a micro-cap company, announced a change in its interim Chief Financial Officer role. While the departure of Kimberly Graper, even for another opportunity, introduces some uncertainty, the immediate appointment of Jeffrey Church, a former Executive VP and CFO of the company, provides crucial continuity. Mr. Church's extensive prior experience with Imunon and other life science companies is a positive factor, mitigating the potential disruption of an executive transition. The compensation structure for Mr. Church reflects the importance of this role for the company.

At the time of this filing, IMNN was trading at $3.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.3M. The 52-week trading range was $2.99 to $41.22. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed IMNN - Latest Insights

IMNN
Mar 31, 2026, 8:50 AM EDT
Filing Type: 10-K
Importance Score:
9
IMNN
Mar 31, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
7
IMNN
Mar 31, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
IMNN
Mar 25, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
9
IMNN
Mar 23, 2026, 4:16 PM EDT
Filing Type: 8-K
Importance Score:
8
IMNN
Mar 23, 2026, 4:15 PM EDT
Filing Type: 424B5
Importance Score:
9
IMNN
Feb 05, 2026, 8:05 AM EST
Filing Type: 8-K
Importance Score:
8
IMNN
Jan 07, 2026, 5:15 PM EST
Filing Type: 8-K
Importance Score:
7